All data are based on the daily closing price as of July 22, 2024
l

Lotus Pharmaceutical

1795.TW
8.62 USD
-0.02
-0.23%

Overview

Last close
8.62 usd
Market cap
2.28B usd
52 week high
11.22 usd
52 week low
6.44 usd
Target price
13.24 usd

Valuation

P/E
18.7915
Forward P/E
N/A
Price/Sales
5.3337
Price/Book Value
5.2181
Enterprise Value
2.54B usd
EV/Revenue
5.9124
EV/EBITDA
14.5921

Key financials

Revenue TTM
506.31M usd
Gross Profit TTM
237.63M usd
EBITDA TTM
175.73M usd
Earnings per Share
0.46 usd
Dividend
N/A usd
Total assets
1.07B usd
Net debt
256.71M usd

About

Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, cardiology, nephrology, women's health, anti-obesity, and central nervous system diseases. The company also provides over-the-counter products. In addition, it engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical products; marketing activities; market planning and business information services; and consultancy services on health management, health technology, and trading information services. Further, the company offers management consultancy services; pharmaceutical regulatory affairs project management, and data collection and agency services; healthcare consultancy services and operates as a contract research organization. The company has strategic partnership with NRX Pharmaceuticals. Lotus Pharmaceutical Co., Ltd. was incorporated in 1966 and is headquartered in Taipei City, Taiwan.
  • Symbol
    1795.TW
  • Exchange
    TW
  • Isin
    TW0001795003
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Ms. Eeling Chan
  • Headquarter
    Taipei
  • Web site
    https://www.lotuspharm.com.tw
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top